Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Genetics

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 49 articles:
HTML format



Single Articles


    January 2024
  1. WANG Y, He M, He T, Ouyang X, et al
    Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers.
    Br J Cancer. 2024 Jan 22. doi: 10.1038/s41416-023-02555.
    PubMed     Abstract available


  2. HALLAL SM, Tuzesi A, Sida LA, Xian E, et al
    Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a 'liquid gold' biopsy.
    Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02548.
    PubMed     Abstract available


    December 2023
  3. GRASSMANN F, Malarstig A, Dahl L, Bendes A, et al
    The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.
    Br J Cancer. 2023 Dec 22. doi: 10.1038/s41416-023-02541.
    PubMed     Abstract available


    September 2023
  4. PAYNE K, Brooks J, Batis N, Khan N, et al
    Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping.
    Br J Cancer. 2023 Sep 21. doi: 10.1038/s41416-023-02428.
    PubMed     Abstract available


  5. YANG Y, Xu S, Jia G, Yuan F, et al
    Integrating genomics and proteomics data to identify candidate plasma biomarkers for lung cancer risk among European descendants.
    Br J Cancer. 2023 Sep 7. doi: 10.1038/s41416-023-02419.
    PubMed     Abstract available


  6. LIU Z, Duan T, Zhang Y, Weng S, et al
    Radiogenomics: a key component of precision cancer medicine.
    Br J Cancer. 2023;129:741-753.
    PubMed     Abstract available


    August 2023
  7. VAN MOURIK A, Tonkin-Hill G, O'Farrell J, Waller S, et al
    Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
    Br J Cancer. 2023;129:301-308.
    PubMed     Abstract available


    July 2023
  8. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    PubMed     Abstract available


    June 2023
  9. XU L, Su H, Zhao S, Si H, et al
    Development of the semi-dry dot-blot method for intraoperative detecting micropapillary component in lung adenocarcinoma based on proteomics analysis.
    Br J Cancer. 2023;128:2116-2125.
    PubMed     Abstract available


  10. KITAGAWA A, Osawa T, Noda M, Kobayashi Y, et al
    Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.
    Br J Cancer. 2023;128:2206-2217.
    PubMed     Abstract available


    May 2023
  11. RASMUSSEN SV, Wozniak A, Lathara M, Goldenberg JM, et al
    Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma.
    Br J Cancer. 2023;128:1941-1954.
    PubMed     Abstract available


    April 2023
  12. ROSSWOG C, Fassunke J, Ernst A, Schomig-Markiefka B, et al
    Genomic ALK alterations in primary and relapsed neuroblastoma.
    Br J Cancer. 2023;128:1559-1571.
    PubMed     Abstract available


    March 2023
  13. CIFUENTES GA, Santiago A, Mendez Blanco L, Fueyo M, et al
    Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.
    Br J Cancer. 2023;128:857-876.
    PubMed     Abstract available


    February 2023
  14. NJOKU K, Pierce A, Geary B, Campbell AE, et al
    Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.
    Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02139.
    PubMed     Abstract available


  15. CHEN G, Zhang J, Fu Q, Taly V, et al
    Integrative analysis of multi-omics data for liquid biopsy.
    Br J Cancer. 2023;128:505-518.
    PubMed     Abstract available


    December 2022
  16. ZHANG X, Yu Z, Xu Y, Chao Y, et al
    Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.
    Br J Cancer. 2022;127:2154-2165.
    PubMed     Abstract available


    November 2022
  17. NEUMANN O, Burn TC, Allgauer M, Ball M, et al
    Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.
    Br J Cancer. 2022;127:1540-1549.
    PubMed     Abstract available


  18. HILTBRUNNER S, Fleischmann Z, Sokol ES, Zoche M, et al
    Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Br J Cancer. 2022;127:1997-2005.
    PubMed     Abstract available


    October 2022
  19. JAN YH, Tan KT, Chen SJ, Yip TTC, et al
    Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.
    Br J Cancer. 2022;127:1304-1311.
    PubMed     Abstract available


    September 2022
  20. LI H, Sun Z, Xiao R, Qi Q, et al
    Stepwise evolutionary genomics of early-stage lung adenocarcinoma manifesting as pure, heterogeneous and part-solid ground-glass nodules.
    Br J Cancer. 2022;127:747-756.
    PubMed     Abstract available


  21. PRUIS MA, Groenendijk FH, Badloe KS, van Puffelen A, et al
    Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.
    Br J Cancer. 2022;127:776-783.
    PubMed     Abstract available


    August 2022
  22. JUNG S, Armstrong E, Wei AZ, Ye F, et al
    Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01942.
    PubMed     Abstract available


  23. HSIEH CC, Hsu SH, Lin CY, Liaw HJ, et al
    CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01946.
    PubMed     Abstract available


  24. INGEBRIKTSEN LM, Finne K, Akslen LA, Wik E, et al
    A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01953.
    PubMed     Abstract available


    July 2022
  25. ROBINSON N, Casement J, Gunter MJ, Huybrechts I, et al
    Anti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors.
    Br J Cancer. 2022;127:288-300.
    PubMed     Abstract available


  26. GLEWIS S, Alexander M, Khabib MNH, Brennan A, et al
    A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
    Br J Cancer. 2022;127:126-136.
    PubMed     Abstract available


    June 2022
  27. CATANZARO D, Milani G, Bozza A, Bernardi M, et al
    Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01865.
    PubMed     Abstract available


    March 2022
  28. BOLGER JC, Donohoe CL, Lowery M, Reynolds JV, et al
    Advances in the curative management of oesophageal cancer.
    Br J Cancer. 2022;126:706-717.
    PubMed     Abstract available


    January 2022
  29. LAL N, Chan DKH, Ng ME, Vermeulen L, et al
    Primary tumour immune response and lymph node yields in colon cancer.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01700.
    PubMed     Abstract available


  30. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    PubMed     Abstract available


    December 2021
  31. ZHANG X, Li X, He Y, Law PJ, et al
    Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01655.
    PubMed     Abstract available


    November 2021
  32. ROMUALDO CARDOSO S, Gillespie A, Haider S, Fletcher O, et al
    Functional annotation of breast cancer risk loci: current progress and future directions.
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01612.
    PubMed     Abstract available


  33. HAKOZAKI K, Tanaka N, Takamatsu K, Takahashi R, et al
    Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma.
    Br J Cancer. 2021;125:1533-1543.
    PubMed     Abstract available


    September 2021
  34. CHEN D, Bao X, Zhang R, Ding Y, et al
    Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
    Br J Cancer. 2021;125:994-1002.
    PubMed     Abstract available


  35. CRISPIN-ORTUZAR M, Sala E
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    PubMed     Abstract available


    August 2021
  36. GEVAERT O
    Meta-learning reduces the amount of data needed to build AI models in oncology.
    Br J Cancer. 2021;125:309-310.
    PubMed     Abstract available


    July 2021
  37. LEI JT, Zhang B
    Proteogenomics drives therapeutic hypothesis generation for precision oncology.
    Br J Cancer. 2021;125:1-3.
    PubMed     Abstract available


    June 2021
  38. LEE KH, Chen WS, Jiang JK, Yang SH, et al
    The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
    PubMed     Abstract available


    May 2021
  39. SINGH G, Manjila S, Sakla N, True A, et al
    Radiomics and radiogenomics in gliomas: a contemporary update.
    Br J Cancer. 2021 May 6. pii: 10.1038/s41416-021-01387.
    PubMed     Abstract available


    February 2021
  40. ROSENTHAL R, Swanton C, McGranahan N
    Understanding the impact of immune-mediated selection on lung cancer evolution.
    Br J Cancer. 2021 Feb 24. pii: 10.1038/s41416-020-01232.
    PubMed     Abstract available


    January 2021
  41. BARROW TM, Nakjang S, Lafta F, Bilotkach K, et al
    Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.
    Br J Cancer. 2021;124:474-483.
    PubMed     Abstract available


    October 2020
  42. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    PubMed     Abstract available


    July 2020
  43. HORNIGOLD N, Dunn KR, Craven RA, Zougman A, et al
    Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion.
    Br J Cancer. 2020;123:137-147.
    PubMed     Abstract available


    May 2020
  44. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    PubMed     Abstract available


    March 2020
  45. LUCA BA, Moulton V, Ellis C, Edwards DR, et al
    A novel stratification framework for predicting outcome in patients with prostate cancer.
    Br J Cancer. 2020 Mar 20. pii: 10.1038/s41416-020-0799.
    PubMed     Abstract available


  46. POWLEY IR, Patel M, Miles G, Pringle H, et al
    Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
    Br J Cancer. 2020;122:735-744.
    PubMed     Abstract available


    February 2020
  47. NIEGISCH G
    Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
    Br J Cancer. 2020;122:453-454.
    PubMed     Abstract available


  48. VISSIO E, Metovic J, Osella-Abate S, Bertero L, et al
    Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Br J Cancer. 2020;122:382-387.
    PubMed     Abstract available


    January 2020
  49. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Genetics is free of charge.